Study design
allergic symptoms, allergy, dust mite allergen extract, ’ pain
ADVERSE REACTIONS, ALLERGY
This is a prospective randomized controlled study with 25 patients receiving ICLIT (Study design. The trial included 1 pre-treatment screening visit, 3 treatment visits, 5 follow-up visits within 36 months after treatment. ICLIT, intra-cervical lymphatic immunotherapy; SCIT, subcutaneous immunotherapy Eav, eosinophils absolute value; SPT, skin prick test; tIgE, total IgE; sIgE, specific IgE.Eligibility was determined at the first visit when patients were required for a questionnaire including allergic symptoms, use of rescue medication, and quality of life. Also, The qualification of patients was determined by SPT and collecting blood samples of patients for evaluating eosinophils absolute value, total serum dust mite IgE and Derp and Derf-specific IgE. Based on the results of the allergy tests, and in accordance with the principle of randomization, patients received the first injection of Arroger-standardized dust mite allergen extract (Novo- Helisen-Depot, Allergopharma GmbH &Co. KG, Reinbek, Germany) with the specific injection regimen shown in 2.4. Patients’ pain perception and adverse reactions that occurred need to be recorded throughout the treatment. Patients were followed-up by hospital visit or phone interview for a questionnaire related to the first visit at 3 month, 6 month,12 month, 24 month and 36 month after treatment. Besides, SPT and blood sample were required at 12-month and 36-month follow-up so as to assess the effectiveness of treatment.